SIK2 and ovarian carcinoma: Research indicates that the knockdown of SIK2 in colorectal and ovarian cancer cells results in a 50% reduction in cellular glucose metabolism, underscoring SIK2’s significant regulatory influence on this metabolic pathway [21,22].